Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma among Diabetic Patients in Asia

Medicine (United States)

Volumn 94, Issue 24, 2015, Pages

  Chen, Hsin Hung ^a,b,c   Lin, Ming Chia ^d   Muo, Chih Hsin ^e   Yeh, Su Yin ^f   Sung, Fung Chang ^e,g   Kao, Chia Hung ^g,h  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c Nantou Christian Hospital   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g Pediatric Dentistry   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; METFORMIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASIA; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; ICD-9-CM; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RISK FACTOR; AGED; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; LIVER NEOPLASMS; RISK;

AGED; ASIA; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 84941332486     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001013     Document Type: Article

References (40)

1. Joslin EP, Lombard HL, Burrows RE, et al. Diabetes and cancer. N Engl J Med. 1959;260:486–488.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.
3. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–1123.
4. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605–1609.
5. Nomura K, Hamamoto Y, Takahara S, et al. Relationship between carotid intima-media thickness and silent cerebral infarction in Japanese subjects with type 2 diabetes. Diabetes Care. 2010;33:168–170.
6. Gao C, Yao SK. Diabetes mellitus: a ‘‘true’’ independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int. 2009;8:465–473.
7. Lawson DH, Gray JM, McKillop C, et al. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med. 1986;61:945–955.
8. Noto H, Osame K, Sasazuki T, et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications. 2010;24:345–353.
9. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539.
10. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15:280–288.
11. Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 1994;19:616–627.
12. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140.
13. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539.
14. Doshi SM, Kulkarni PA, Liao JM, et al. The impact of statin and macrolide use on early survival in patients with Pneumococcal pneumonia. Am J Med Sci. 2013;345:173–177.
15. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007;28:664–672.
16. Sutter AP, Maaser K, Hopfner M, et al. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors: synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol. 2005;43:808–816.
17. Tatsuta M, Iishi H, Baba M, et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague–Dawley rats. Br J Cancer. 1998;77:581–587.
18. H, Graf. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion. 2008;78:34–38.
19. Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol. 2003;23:1055–1069.
20. Wong WW, Tan MM, Xia Z, et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 2001;7:2067–2075.
21. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res. 2001;7:2898–2907.
22. Paragh G, Kertai P, Kovacs P, et al. HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res. 2003;23:3949–3954.
23. Han KH, Rha SW, Kang HJ, et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol. 2012;6:340–351.
24. Lai SW, Liao KF, Lai HC, et al. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28:485–492.
25. Chiu HF, Ho SC, Chen CC, et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106:894–898.
26. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE. 2013;8:e71583.
27. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012;7:e33411.
28. Zhang ZJ, Zheng ZJ, Shi R, et al. Kip metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:2347–2353.
29. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–1461.
30. Krakoff J, Clark JM, Crandall JP, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring). 2010;18:1762–1767.
31. White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997;40 (suppl 2):S2–S17.
32. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2:778–790.
33. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010;49:662–671.
34. Algire C, Moiseeva O, Deschenes-Simard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila). 2012;5:536–543.
35. Bodmer M, Becker C, Meier C, et al. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:280–286.
36. Wang SY, Chuang CS, Muo CH, et al. Metformin and the incidence of cancer in patients with diabetes: a nested case-control study. Diabetes Care. 2013;36:e155–e156.
37. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007;67:391–397.
38. Grotenhuis BA, Wijnhoven BP, van Lanschot JJ. Cancer stem cells and their potential implications for the treatment of solid tumors. J Surg Oncol. 2012;106:209–215.
39. Yi G, He Z, Zhou X, et al. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. Int J Oncol. 2013;43:1503–1510.
40. Chung HH, Moon JS, Yoon JS, et al. The relationship between metformin and cancer in patients with type 2 diabetes. Diabetes Metab J. 2013;37:125–131.